| Literature DB >> 33387157 |
Owen Dean1, Seher Anjum1, Bryan Hess2, Dima A Hammoud3, Deena Athas4, Joseph Wheat5, Peter R Williamson6.
Abstract
We present a case of central nervous system (CNS) histoplasmosis in a previously healthy adult with hepatitis C (HCV) presenting with neurological symptoms refractory to antifungal therapy and ventriculoperitoneal (VP) shunting 4 months after initial diagnosis. Persistent symptoms were thought to be inflammatory rather than infectious given negative cerebrospinal fluid (CSF) and serum fungal antigens. The patient promptly improved after initiation of corticosteroid therapy. Elevated CSF cytokines and regional enhancement on brain MRI resolved with corticosteroid treatment. This is the first case of Histoplasma-associated post-infectious inflammatory response syndrome (Histo-PIIRS) documented by CSF cytokine reduction in response to corticosteroid therapy.Entities:
Keywords: Fungal meningitis; central nervous system; histoplasma; inflammation
Mesh:
Substances:
Year: 2021 PMID: 33387157 PMCID: PMC7776302 DOI: 10.1007/s10875-020-00954-9
Source DB: PubMed Journal: J Clin Immunol ISSN: 0271-9142 Impact factor: 8.317
Fig. 1Longitudinal cerebrospinal fluid findings and case timeline. a-d Indicated CSF parameters. White blood count (WBC). The vertical dotted line represents the start of prednisone therapy. The solid horizontal lines represent normal values (CSF glucose > 50 mg/dL, CSF protein < 80 mg/dL, WBC < 5/μL). Tumor necrosis factor-alpha, IL-2, IL-12, IL-4, IL-5, IL-5, IL-10, IL-13, IL-17, and IL-1-β were not significantly elevated in the CSF at any time point and therefore not shown. CSF cytokines obtained by ARUP Laboratories. WBC: white blood cell count. Soluble CD25 is also known as IL-2 receptor
Diagnostic studies in CNS histoplasmosis
| Parameters [ | Results, days after diagnosis | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | 0 | 114 | 117 | 119 | 122 | 126 | 161 | 183 | 217 | 658 | |
| CSF antibody EIA | ||||||||||||
| IgG | 82.2 | 94.8 | 80a | |||||||||
| IgM | 31.1 | 97.4 | 21.6a | |||||||||
| CSF antigen EIA | 78.0 | 96.6 | Neg. a | |||||||||
| CSF beta-D-glucan (pg/mL)* | 53.2 | 86.9 | < 31a | |||||||||
| CSF antibody by CF** | 50.0 | 92.9 | ||||||||||
| Yeast phase | ND | ND | ≥ 1:16 | < 1:8 | 1:4 | 1:8 | 1:8 | < 1:1 | < 1:1 | |||
| Mycelial phase | ND | ND | < 1:1 | < 1:8 | 1:1 | < 1:1 | < 1:1 | < 1:1 | < 1:1 | |||
| CSF fungal detection by PCR | ND | ND | Neg. c | |||||||||
| CSF culture | 19.1 | 100.0 | Neg. a | |||||||||
| Serum antibody EIA | ||||||||||||
| IgG | ND | ND | 80a | |||||||||
| IgM | ND | ND | Neg. a | |||||||||
| Serum antigen EIA | 77 | ND | Neg. a | Neg. a | Neg. a | |||||||
| Serum beta-D-glucan (pg/mL) | ND | ND | >500 a | |||||||||
| Urine antigen EIA | 77 | ND | Neg. a | < 0.5ngb | ||||||||
EIA enzyme immunoassay, CF complement fixation, PCR polymerase chain reaction, Neg negative, ND no data
*Federal Drug Administration approved cutoff for CSF (1,3) beta-D-glucan is 31 pg/mL
**Detection of antibody by CF in undiluted CSF is considered positive
aMiraVista Diagnostics
bQuest Diagnostics
cUniversity of Washington Molecular Diagnostics Microbiology Section
Fig. 2Brain MRI imaging. a-c Axial and sagittal-enhanced T1-weighted images which obtained pre-steroid demonstrate abnormal enhancement in the internal auditory canals bilaterally (small white arrows), abnormal enhancement in the prepontine cistern (arrowhead), and meningeal enhancement along the trigeminal nerves, anterior aspect of the pons, medulla and along the inferior cerebellum (open white arrows). d-e Decreased abnormal enhancement within the auditory canals (small white arrows) and in the prepontine cistern (arrowhead) after corticosteroid administration (e) compared to pre-treatment (d)